{
  "events": [
    {
      "drug": "Paxalisib (PNOC022) View Clinical Trial Data",
      "indication": "Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMGs).",
      "company": "Kazia Therapeutics Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/02/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "Roflumilast Cream (ARQ-151) - (INTEGUMENT-1 and INTEGUMENT-2)",
      "indication": "Atopic dermatitis",
      "company": "Arcutis Biotherapeutics Inc.",
      "pdufa_date": "07/07/2024 ET",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "NurOwn View Clinical Trial Data",
      "indication": "Amytrophic lateral sclerosis (ALS)",
      "company": "Brainstorm Cell Therapeutics Inc.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/08/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "SULANDA (surufatinib)",
      "indication": "Metastatic pancreatic ductal adenocarcinoma (\"PDAC\") in China",
      "company": "HUTCHMED (China) Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/09/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "HMPL-523 - (ESLIM-01) BTD",
      "indication": "Primary immune thrombocytopenia (ITP)",
      "company": "HUTCHMED (China) Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/09/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "Sovleplenib - (ESLIM-02)",
      "indication": "Warm antibody autoimmune hemolytic anemia (wAIHA)",
      "company": "HUTCHMED (China) Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/09/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "HMPL-306 - (RAPHAEL)",
      "indication": "Relapsed / refractory acute myeloid leukemia (AML)",
      "company": "HUTCHMED (China) Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/09/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "RYONCIL (remestemcel-L) - (MSB-GVHD001)",
      "indication": "Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)",
      "company": "Mesoblast Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/12/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "Tumor Treating Fields (TTFields) - (LUNAR) View Clinical Trial Data",
      "indication": "Non-small cell lung cancer (NSCLC)",
      "company": "NovoCure Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/17/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "Tumor Treating Fields (TTFields) - (LUNAR) View Clinical Trial Data",
      "indication": "Non-small cell lung cancer (NSCLC)",
      "company": "Zai Lab Limited",
      "pdufa_date": "",
      "fda_date_no_pdufa": "07/17/2024 ET",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    }
  ]
}